Related Experiment Video

Updated: Aug 14, 2026

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene
08:18

Focus Formation: A Cell-based Assay to Determine the Oncogenic Potential of a Gene

Published on: December 31, 2014

[Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent

C Müller-Tidow1, C Steur, M Mizuki

  • 1Medizinische Klinik A, Universitätsklinikum Münster.

Deutsche Medizinische Wochenschrift (1946)
|October 25, 2002
PubMed
Abstract

Insights

Mutated Flt3 receptors drive acute myeloid leukemia (AML) by promoting cell growth and survival. Targeting PI3-kinase, not just Ras pathways, is crucial for effective Flt3-mutated AML treatment.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • Fms-like tyrosine kinase 3 (FLT3) receptor mutations are common in acute myeloid leukemia (AML) and associated with poor prognosis.
  • These FLT3 mutations are oncogenic, driving leukemic transformation through altered signaling pathways.
  • FLT3 and its signaling intermediates represent potential therapeutic targets in AML.

Purpose of the Study:

  • To investigate the signaling properties of mutated FLT3 receptors.
  • To analyze the effects of inhibiting specific signaling pathways on FLT3-mutated myeloid cells.
  • To determine the therapeutic potential of targeting FLT3 signaling intermediates in AML.

Main Methods:

  • Isolated mRNA from two AML patients to express wild-type and mutant FLT3 isoforms in 32D cells.
  • Assessed cell proliferation, survival, signaling intermediate activation, and gene expression.
  • Evaluated the impact of Ras, MAP-Kinase, and PI3-Kinase inhibition on cellular functions.

Main Results:

  • Mutant FLT3 (FLT3-ITD) expression induced factor-independent proliferation and survival in 32D cells.
  • FLT3-ITD activated Ras-, PI3-kinase-, STAT5-, and STAT3-dependent pathways, leading to STAT target gene induction.
  • PI3-kinase inhibition abrogated FLT3-ITD-driven growth and apoptosis resistance, while Ras/MAP-kinase inhibition had partial effects.

Conclusions:

  • Inhibition of Ras-dependent signaling alone is insufficient to overcome the effects of FLT3 mutations in myeloid cells.
  • Therapeutic strategies targeting FLT3-driven AML may require combined inhibition of multiple pathways, including PI3-kinase.
  • Ras inhibitors alone may not be sufficient for treating FLT3-mutated AML.

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...